Compare Arm Holdings plc (ARM) vs Cassava Sciences Inc (FLNA) Price & Performance

ARM Holdings trades at $323.39, down 1.37% over 24 hours, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The company reported robust revenue growth to $4.01B in 2025, with net income of $792M, though valuation ratios like P/E of 380.46 reflect premium pricing. Recent news highlights ARM's role in AI infrastructure and data center expansion, driving investor optimism.

Outlook remains positive with analyst consensus favoring buy ratings (74.07%) and a $321.65 price target, but risks include high valuation sensitivity and competitive pressures in the semiconductor space. Upside potential hinges on continued AI-driven demand and execution of growth initiatives like the AGI CPU launch.

FLNA trades at $1.18, down 0.84% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -79.59% and ROA at -62.5%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Q1 2026 financial results and scientific presentations on TSC-related epilepsy therapies. Analyst consensus remains positive with 67% buy ratings.

While analyst sentiment is bullish, FLNA faces significant fundamental challenges with negative cash flow and earnings. The primary investment opportunity lies in successful drug development, but risks include sustained cash burn and clinical trial outcomes. Investors should weigh the high-risk biotech profile against potential pipeline catalysts.